Transcode Therapeutics Inc (RNAZ)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $22.35M
Last updated: Nov 17, 2026 at 4:15 PM ET
Transcode Therapeutics Inc (RNAZ) Statistics
Transcode Therapeutics (RNAZ) has a market cap of $22.35M and an enterprise value of $20.82M. Its share count is up 1275.49% from a year earlier.
Total Valuation
Enterprise value is 6.83% below the market cap, as cash exceeds debt.
| Market Cap | $22.35M |
|---|---|
| Enterprise Value | $20.82M |
| Latest price (Nov 17, 2026) | $1.40 |
Key Dates
| Last Earnings Date | Aug 14, 2026 |
|---|---|
| Fiscal Year End | December |
Price Statistics
The stock is down 84.85% over 52 weeks and trades 14.63% below its 50-day average.
| Beta (1Y) | 0.76 |
|---|---|
| 52-Week Change | -84.85% |
| 1-Month Change | -17.65% |
| 3-Month Change | -56.39% |
| 6-Month Change | -77.34% |
| 5-Year Change | -100.00% |
| Total Return (1Y) | -84.85% |
| Total Return (3Y CAGR) | -94.75% |
| Total Return (5Y CAGR) | -94.13% |
| Return vs SPY (1Y) | -96.06% |
| Max Drawdown (1Y) | -89.30% |
| Max Drawdown (3Y) | -99.99% |
| Sharpe Ratio (1Y) | -1.96 |
| Correlation with SPY (1Y) | 0.11 |
| 50-Day Average | $1.64 |
| 200-Day Average | $5.64 |
| 52-Week Range | $1.29 to $12.60 |
| RSI (14 Days) | 38.2 |
| Average Volume (20 Days) | 23.81K |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 0.96x current liabilities, and total debt is 0.10x shareholder equity.
| Current Ratio | 0.96x |
|---|---|
| Quick Ratio | 0.96x |
| Debt / Equity | 0.10x |
Returns and Efficiency
Return on invested capital is -412.71% and return on equity is -452.25% over the last 12 months.
| Return on Equity (ROE) | -452.25% |
|---|---|
| Return on Assets (ROA) | -324.83% |
| Return on Invested Capital (ROIC) | -412.71% |
Scores
RNAZ has a Piotroski F-Score of 3 of 9, in the average band of 3 to 7.
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Piotroski F-Score | 3 of 9 |
|---|---|
| Piotroski Strength | Average |
Income Statement
Revenue was $0 over the last 12 months.
| Revenue | $0 |
|---|---|
| Operating Income | -$150.26M |
| Pretax Income | -$145.23M |
| Net Income | -$145.36M |
| Reported EPS (TTM) | -$50.68 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 71.82% of the $44.75M in total assets.
| Cash and Equivalents | $4.64M |
|---|---|
| Total Debt | $3.11M |
| Net Cash | $1.53M |
| Net Cash Per Share | $0.13 |
| Working Capital | -$284.40K |
| Shareholder Equity | $32.14M |
| Book Value Per Share | $2.80 |
| Tangible Book Value | -$5.90M |
| Total Assets | $44.75M |
| Total Liabilities | $12.61M |
Balance sheet as of Sep 30, 2026.
Cash Flow
| Operating Cash Flow | -$26.18M |
|---|---|
| FCF Per Share | -$1.55 |
| Depreciation and Amortization | $114.47K |
Trailing 12 months through Sep 30, 2026.
Dividends and Yields
RNAZ does not pay a dividend.
| Buyback Yield | 0.00% |
|---|---|
| Shareholder Yield | 0.00% |
Stock Splits
The last split was a 1-for-28 reverse split on May 15, 2025.
| Last Split Date | May 15, 2025 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:28 |
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About RNAZ
What is RNAZ's market cap?
Transcode Therapeutics has a market cap of $22.35M. Its enterprise value, which adds debt and subtracts cash, is $20.82M.
How many shares of RNAZ are outstanding?
Transcode Therapeutics has 11.47M shares outstanding. The count is up 1275.49% from a year earlier.
Does RNAZ pay a dividend?
No. Transcode Therapeutics does not pay a dividend.
How much debt does RNAZ have?
Transcode Therapeutics has $3.11M of total debt and $4.64M of cash and equivalents, a net cash position of $1.53M.
RNAZ pages: Overview, Charting, Earnings, Financials, Statistics, Competitors